General MedicationsORALStandard
DEFERASIROX
DEFERASIROX
Standard Dose
125MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview DEFERASIROX is listed in Drugs@FDA under application 210920 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient DEFERASIROX Form and strength TABLET, FOR SUSPENSION;ORAL - 125MG Sponsor BIONPHARMA Submission history Latest submission status date: 2023-09-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview DEFERASIROX is listed in Drugs@FDA under application 210920 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DEFERASIROX Form and strength TABLET, FOR SUSPENSION;ORAL - 125MG Sponsor BIONPHARMA Submission history Latest submission status date: 2023-09-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.